Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Osteoporosis, Postmenopausal Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

10 recruiting trials for Osteoporosis, Postmenopausal. Eligibility criteria explained in plain English.

TrialFinderData lists 10 Osteoporosis, Postmenopausal clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 4 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by University Hospital, Clermont-Ferrand (1), Khyber Medical University Peshawar (1), Istanbul Physical Medicine Rehabilitation Training and Research Hospital (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Cohort follow-up (other, 1 trial), followed by Alendronate, Ibandronate; Risedronate, Teriparatide.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Track Osteoporosis, Postmenopausal trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05228262

Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis

This study aims to follow a cohort of osteoporotic patients treated with anti-osteoporotic drugs and to evaluate the impact of these treatments on the...

Sponsor: University Hospital, Clermont-FerrandEnrolling: 1501 location
RECRUITINGNCT07242612

Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis

This study investigates the use of blood tests known as Bone Turnover Markers (BTMs) to quickly monitor the effectiveness of osteoporosis treatment in postmenopausal women....

Sponsor: Khyber Medical University PeshawarEnrolling: 401 location
RECRUITINGNCT07253493

Effect of Mechanical Loading and Bone Loss on Motor Neuron Activity-H-Reflex Relationship

Weight-bearing exercises (e.g., running, jumping, whole-body vibration) are widely practiced due to their beneficial effects on bone development and their role in the prevention...

Sponsor: Istanbul Physical Medicine Rehabilitation Training and Research HospitalEnrolling: 241 location
RECRUITINGNCT06462833

Health Literacy's Impact on Exercise Habits and Medication Adherence in Postmenopausal Osteoporosis

Postmenopausal osteoporosis is characterized by low bone mass and increased fracture risk. Treatment includes exercise, nutrition, supplements, and medications like...

Sponsor: Gazi UniversityEnrolling: 601 location
RECRUITINGPhase 4NCT06938152

Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients

This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of...

Sponsor: National Taiwan University HospitalEnrolling: 701 location
RECRUITINGNCT06655701

Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis

The primary aim of our study is to evaluate the presence of stress urinary incontinence in postmenopausal patients with and without osteoporosis, determine its impact on quality...

Sponsor: Beylikduzu State HospitalEnrolling: 1001 location
RECRUITINGNCT06525688

New Biomarkers and Therapeutic Targets in Osteoporosis Via Omics Technologies

This study aims to discover novel biomarkers and therapeutic targets for osteoporosis through the use of advanced omics technologies, including proteomics and metabolomics. By...

Sponsor: National and Kapodistrian University of AthensEnrolling: 601 location
RECRUITINGNCT05688969

Mechanisms of Anabolic Osteoporosis Therapy

The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.

Sponsor: Massachusetts General HospitalEnrolling: 161 location
RECRUITINGNCT05575167

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

A 24-month prospective, open-label, randomized, multicenter, multinational, non-inferiority pragmatic clinical trial evaluating zoledronate single or double infusion versus oral...

Sponsor: 424 General Military HospitalEnrolling: 1259 locations
RECRUITINGNCT06487130

Virtual perI-/Menopause Registry of AusTrALia

13 million (50.7%) Australians are born with ovaries, 14% (\~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as \>12...

Sponsor: Bespoke Clinical ResearchEnrolling: 100001 location

Frequently Asked Questions

There are currently 10 clinical trials for Osteoporosis, Postmenopausal, with 10 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Osteoporosis, Postmenopausal, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Osteoporosis, Postmenopausal, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.